Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated BEP vs Standard BEP in Metastatic Germ Cell Tumours
NCT02582697Phase 3Recruiting
- Sponsor
- University of Sydney
- Start
- Feb 2014
- Primary completion
- Dec 2029
- Modality
- Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of bleomycin, etoposide and Cisplatin micelle injection (HA132) in germ cell tumor (GCT) (2 arms), sponsored by University of Sydney. Primary endpoint: Progression-free survival at 5 years. Started Feb 2014; status: recruiting.
02
Drugs
bleomycinetoposideCisplatin micelle injection (HA132)
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT02582697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582697.